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rapamycin is probably not unique to
mTORC1, so addressing these questions
will have to rely on additional inhibitors or
conditional gene ablation that specifically
interfere with mTORC1 or mTORC2.
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Mutations in the human NLRP3 gene cause interleukin-1b-related autoinflammatory syndromes. In this issue
of Immunity, Brydges et al. (2009) and Meng et al. (2009) report the characterization of Nlrp3 gene-targeted
mice harboring mutations mimicking those causing disease in humans.NLRP3 (also known as cryopyrin and
Nalp3) is a member of the Nod-like
receptor (NLR) family of intracellular
pattern-recognition molecules detecting
microbial- and danger-associated molec-
ular patterns (Fritz et al., 2006). NLRP3,
like other NLR proteins such as NLRP1
and NLRP4, plays a critical role in the
activation of caspase-1-containing co-
mplexes, also known as inflammasomes.
Upon activation by the NLRP3 inflamma-
some, caspase-1 cleaves the proforms
of interleukin-1b (IL-1b) and IL-18 into their
mature forms. Importantly, the present
belief is that IL-1b maturation requires
a two-step process: first, upregulation of
pro-IL-1b transcription by Toll-like re-
ceptor (TLR) ligands, such as lipopolysac-
charide; and second, activation of a cas-
pase-1 inflammasome (Figure 1).
In the past few years, a considerable
and diverse array of stimuli have been
shown to trigger NLRP3 activation (Benko
et al., 2008). Remarkably, NLRP3 seems
to be activated by microbial molecular
patterns (bacterial RNA, double-stranded
RNA, and muramyl dipeptide), microbial
toxins (aerolysin and nigericin), xenocom-
pounds and crystals (asbestos, silica, andaluminum hydroxide), and endogenous
danger signals (potassium efflux, extra-
cellular adenosine triphosphate [ATP],
b-amyloid, and uric acid), suggesting
that NLRP3 probably senses a common
effector downstream of all these trig-
gers. At present, the nature of this puta-
tive common effector remains a matter
of debate but might be associated with
reactive oxygen species generation or
damage the lysosome (Franchi et al.,
2009).
Mutations in the gene coding for NLRP3
have been shown to be associated with
Muckle-Wells syndrome (MWS), familial
cold urticaria (FCU), and chronic infantile
neurological cutaneous and articular syn-
drome (CINCA), which are autoinflamma-
tory syndromes characterized by an
excessive secretion of IL-1b (Martinon
et al., 2009; Ting et al., 2006). Thesemuta-
tions are all found in the exon 3 of the
human gene and generate amino acid
substitutions either inside or at the vicinity
of the central NACHT domain. Although
some mutations predispose to one of
the specific syndromes presented above,
others (such as R260W) are linked tomore
than one type of disease, suggesting thatImmunityother factors may contribute to the onset
of these pathologies.
NLRP3-deficient mice have been ge-
nerated and extensively used in the past
few years, and this animal model has
proven invaluable to identify themolecular
structures and the pathogens detected by
this NLR protein. However, Nlrp3/ mice
offer little informationwith regard tohuman
pathologies characterized by NLRP3 mu-
tations, because these are gain-of-func-
tionmutations. Two studies, by the groups
of Strober and Hoffman, published in this
issue of Immunity (Meng et al., 2009;
Brydges et al., 2009), now report the
generation of gene-targetedmice carrying
mutations that precisely mimic amino acid
substitutions in NLRP3 found to cause
disease susceptibility in humans. Meng
et al. (2009) generated a mouse strain ex-
pressing a R258W mutation in mouse
Nlrp3 gene, corresponding to the R260W
substitution found in humans. In a slightly
different approach, Brydges et al. (2009)
generated two mouse strains carrying
mutations (A350V and L351P; corre-
sponding to mutations A352V and L353P
in humans) downstreamof a LoxP-flanked
neomycin resistance (NeoR) cassette in30, June 19, 2009 ª2009 Elsevier Inc. 761
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PreviewsFigure 1. Activation of the NLRP3 Inflammasome in Wild-Type versus Gene-Targeted Cells
Secretion of mature IL-1b (and also IL-18; not depicted here) requires induction of pro-IL-1b transcription
and translation after activation by Toll-like receptors. Concomitantly, in wild-type cells, NLRP3 is activated
by diverse stimuli (microbial signatures or danger signals) and triggers the formation of a caspase-1 inflam-
masome that cleaves pro-IL-1b into its mature form (left). In Nlrp3mutant cells, mutated NLRP3 is likely to
be constitutively active, thereby not requiring stimulation by upstream stimuli.a reverse orientation. In this setting, ex-
pression of the mutated NLRP3 protein
was conditional to the crossing with Cre
recombinase-expressing mice, and mice
expressing the mutated NLRP3 protein in
all tissues (xCreZ), myeloid cells (xCreL),
or after tamoxifen exposure (inducible ex-
pression; xCreT) were used in the study.
It must be noted that the mutation chosen
by Meng et al. (2009) has been shown to
confer susceptibility to both MWS and
FCU in humans, whereas the substitutions
selected by Brydges et al. (2009) are indi-
vidually selective for MWS (for A352V)
and FCU (for L353P).
The gene-targeted mice generated in
both studies had very severe phenotypes.
R258W mutant newborn mice displayed
delayed growth, decreased weight gain,
and increased mortality; adult animals
were infertile and developed dermatitis
associatedwith increasedsizeof lymphoid
organs. The A350V-CreZ mice died be-
tween days 2 and 14 and displayed
profound growth delays, skin abscesses,
and hair growth and pigmentation defects,
and a similar phenotype was observed in
A350V-CreLmice,demonstratingacentral
role for myeloid cells in these abnormali-
ties. Expression of the L351P NLRP3762 Immunity 30, June 19, 2009 ª2009 Elsevmutant in myeloid cells led to an even
more severe phenotype, with no animals
found alive two days after birth.
A common feature of these mouse
models was the development of severe
cutaneous lesions, including erythema,
abscesses, scaling, and thickening of
both the epidermis and dermis, associ-
ated with the accumulation of inflamma-
tion markers in this tissue. Interestingly,
these observations recapitulate some
but not all of the urticaria-like skin lesions
reported in MWS patients. The skin, but
also other tissues such as lymph nodes,
spleen, and liver, all displayed evidence
of inflammation characterized mainly by
infiltration of granulocytes, and in partic-
ular neutrophils. In contrast, Meng et al.
(2009) reported that R258W mutant mice
did not develop inflammation in the lungs,
kidney, and gut. In support of the role of
granulocyte infiltration in the pathology
observed in these mutant mice, both
studies demonstrated that disease could
be recapitulated if mice expressed the
mutated allele of the gene encoding
NLRP3 only in myeloid cells; Brydges
et al. (2009) achieved this by comparing
A350V-CreZ and A350V-CreL mice, and
Meng et al. (2009) did this by generatingier Inc.bone marrow chimeric mice (through
lethal irradiation and bone marrow recon-
stitution). Despite the fact that T cells dis-
played altered polarization profiles in
mutant mice (see below), both groups
found that this defect was due to the
expression of the mutated NLRP3 in
antigen-presenting cells (APCs), and not
in T cells.
Both groups then went on to study the
immunological status of NLRP3 mutant
mice, and demonstrated that inflamma-
tion was characterized by a T helper 17
(Th17) cell-skewed phenotype. In partic-
ular, Meng et al. (2009) found that the in-
flamed skin of R258W mutant mice was
substantially enriched in transcripts for
IL-17, and various Th17 cell-related cyto-
kines, as compared to skin samples of
either wild-type or NLRP3 mutant mice
without cutaneous inflammation. In addi-
tion, CD4+ T cells isolated from the lymph
nodes or the spleen of R258W mutant
mice with spontaneous skin inflammation
displayed upregulation of activation ma-
rkers and produced considerably more
IL-17 than WT cells. In addition, inflamed
tissues also expressed, as expected, an
array of inflammatory cytokines, including
IL-1b and TNF, but less so IL-6. Given the
known crucial role for NLRP3 in inflamma-
some activation, both groups then aimed
to determine the role of elevated IL-1b in
disease progression and Th17 polariza-
tion. To do so, Brydges et al. (2009)
treated A350V-CreL mutant mice with
mIL-1 Trap, a mIL-1 soluble inhibitor,
soon after birth and noticed a substantial
increase in survival, compared to vehicle-
injected mice, suggesting a role for IL-1b
in disease onset or progression. Similar
results were obtained when A350V-NeoR
mice were crossed with Il1r/ mice and
then CreL-expressing transgenic animals
to ablate IL-1b signaling. However, in
both experimental settings, the protection
was partial, suggesting that IL-1b-inde-
pendent mechanisms also contributed to
the disease. In the study by Meng et al.
(2009), the authors first performed in vitro
coculture experiments with APCs and
CD4+ T cells and demonstrated that a
diffusible factor from these cells was
responsible for the enhancement of Th17
responses by T cells. Using T cells from
Il1r/ mice, the authors next demon-
strated that IL-1b-dependent signaling
was, at least in part, responsible for
mediating Th17 polarization in vitro. In
Immunity
Previewsagreement with these observations, the
authors also demonstrated that skin
inflammation and IL-17 expression in
R258W mutant mice were decreased
in vivo when animals were treated with
IL1b antibodies. Interestingly, IL17 anti-
bodies also improved skin pathology,
therefore arguing for an important IL-1b-
IL-17 axis in disease progression, at least
in cutaneous tissues.
At the cellular level, both groups iso-
lated bone marrow-derived macrophages
(BMDMs; Meng et al. [2009]) or bone
marrow-derived dendritic cells (BMDCs;
Brydges et al. [2009]) from mutant mice
and explored their IL-1b-dependent re-
sponse after exposure to TLR ligands in
the presence or absence of ATP. Both
studies showed that myeloid cells from
mutant mice did not secrete mature IL-
1b spontaneously, but displayedaconsid-
erably higher sensitivity to TLR ligands
than WT cells and, importantly, did notThe Fate of Huma
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heterogeneous in function, and CD4
CD4+CD25++FoxP3+ Treg cells are pivotal
in controlling undesired self and non-self
immune responses. Importantly, FoxP3+
Treg cells may not be a functionally
homogenous population. Various human
Treg cell subtypes within peripheral
CD4+FoxP3+ T cells have been identified
and can be subgrouped based on the
expression of CD45RA (Seddiki et al.,
2006; Valmori et al., 2005), HLA-DR
(Baecher-Allan et al., 2006), and ICOS (Ito
et al., 2008). Furthermore, FoxP3 can be
expressed in T cells without conferring
regulatory properties. Until now, the dyna-
mic differentiation and fate of the various
FoxP3-expressinghumanperipheralCD4+require exogenous addition of ATP for
optimal activation (Figure 1). This latter
finding is important, because it supports
the notion that NLRP3 mutations associ-
ated with disease susceptibility are gain-
of-function mutations, and that the
mutated NLRP3 protein is constitutively
active and therefore does not require
detection of upstream stimuli. However,
neither study addressed the critical ques-
tion of whether TLR-dependent accumu-
lation of pro-IL1b transcripts is also re-
quired in vivo to ignite IL-1b secretion in
Nlrp3 mutant mice. Indeed, this mode of
activation can be envisioned for tissues
such as the skin, which might come in
contact with microbes after wounding. It
does not explain, however, why Nlrp3
mutantmice did not develop inflammation
in the intestine and the lung, which are co-
nstantly exposed tomicrobes. This obser-
vation suggests that microbial tolerization
mechanisms may efficiently suppress in-n Treg Cells
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al. (2009) demonstrate that FoxP3+ c
5RA expression defines their differe
T cells remained to be clarified. Miyara
et al. (2009) in this issue of Immunity
show that human CD4+FoxP3+ T cells
comprise three distinct subpopulations
with a precise phenotype and fate:CD25++
CD45RA+ (FOXP3lo) resting Treg cells
(rTreg cells), CD25+++CD45RA(FOXP3hi)
activated Treg cells (aTreg cells), which
represent different stages of Treg cell
differentiation and are both suppressive
in vitro, and CD25++CD45RA(FOXP3lo)
cytokine secreting T cells, which lack
suppressive activity.
Positively selected T cells express
CD45RO in the thymus, convert to
CD45RA expression at the time of periph-
Immunitflammasome activation in mucosal sur-
faces in contact with microbes in homeo-
static conditions.
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